Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
BioConferenceLive

Cholesterol Inhibitor Blocks Breast Cancer Growth in Mouse Model

By BiotechDaily International staff writers
Posted on 02 Jul 2014
Image: Space-filling model of the cholesterol molecule (Photo courtesy of Wikimedia Commons).
Image: Space-filling model of the cholesterol molecule (Photo courtesy of Wikimedia Commons).
A low molecular weight drug that inhibits cholesterol biosynthesis was found to block the growth of breast tumors by modifying the ratio of proliferative and antiproliferative estrogen receptors.

Investigators at the University of Missouri (Columbia, USA) used breast cancer cell cultures for in vitro studies and BT-474 breast tumor xenografts in nude mice for in vivo studies of tumor progression. They treated these animals with the drug RO 48-8071, a small-molecule inhibitor of oxidosqualene cyclase (OSC, a key enzyme in cholesterol biosynthesis).

Results published in the July 2014 issue of the journal Breast Cancer Research and Treatment revealed that in vitro exposure of estrogen receptor (ER)-positive human breast cancer cells to pharmacological levels of RO 48-8071 reduced cell viability. Administration of RO 48-8071 to mice with BT-474 tumor xenografts prevented tumor growth, with no apparent toxicity.

At the molecular level it was determined that RO 48-8071 degraded the proliferative alpha estrogen receptor (ERalpha) while concomitantly inducing the antiproliferative protein ERbeta. Chemical inhibition or genetic knockdown of ERbeta prevented RO 48-8071-induced loss of cell viability. Importantly, RO 48-8071 had no effect on the viability of normal human mammary cells.

“Cholesterol is a molecule found in all animal cells and serves as a structural component of cell membranes,” said senior author Dr. Salman Hyder, professor of biomedical sciences at the University of Missouri. “Because tumor cells grow rapidly they need to synthesize more cholesterol. Scientists working to cure breast cancer often seek out alternative targets that might slow or stop the progression of the disease, including the elimination of the cancerous cells. In our study, we targeted the production of cholesterol in cancer cells leading to death of breast cancer cells.”

Related Links:

University of Missouri



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel
Image: A one-year-old baby sits in a brain scanner, called magnetoencephalography (MEG)—a noninvasive approach to measuring brain activity. The baby listens to speech sounds such as “da” and “ta” played over headphones while researchers record her brain responses (Photo courtesy of the Institute for Learning & Brain Sciences at the University of Washington).

Brain Scanner Shows Infants’ Brains Rehearse Speech Sounds Months Before Their First Words

New research in 7- and 11-month-old infants revealed that speech sounds stimulate brain regions that coordinate and plan motor movements for speech. The new study suggests that babies’ brains begin establishing... Read more

Business

view channel

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research. This notable growth... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.